EP Patent

EP1744748A4 — Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes

Assigned to Celgene Corp · Expires 2009-08-12 · 17y expired

What this patent protects

Patent listed against Otezla.

Drugs covered by this patent

Patent Metadata

Patent number
EP1744748A4
Jurisdiction
EP
Classification
—
Expires
2009-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.